These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30763368)

  • 1. SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients.
    Begic E; Hadzidedic S; Kulaglic A; Ramic-Brkic B; Begic Z; Causevic M
    PLoS One; 2019; 14(2):e0212261. PubMed ID: 30763368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Levels of Coagulation Factor XI in Plasma Are Related to Alzheimer's Disease Diagnosis.
    Begic E; Hadzidedic S; Obradovic S; Begic Z; Causevic M
    J Alzheimers Dis; 2020; 77(1):375-386. PubMed ID: 32804133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Terminal Pro-B Type Natriuretic Peptide is Associated with Mild Cognitive Impairment in the General Population.
    Kara K; Mahabadi AA; Weimar C; Winkler A; Neumann T; Kälsch H; Dragano N; Moebus S; Erbel R; Jöckel KH; Jokisch M
    J Alzheimers Dis; 2017; 55(1):359-369. PubMed ID: 27636851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics based identification of differential plasma proteins and changes in white matter integrity as markers in early detection of mild cognitive impaired subjects at high risk of Alzheimer's disease.
    Kumar A; Singh S; Verma A; Mishra VN
    Neurosci Lett; 2018 May; 676():71-77. PubMed ID: 29649488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
    Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
    Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of thiol-disulfıte balance, ischemıa albumın modıfıcation and seruloplazmine as a new oxidatıve stress in mild cognitive impairment and early stage alzheimer's disease patients.
    Gündüztepe Y; Bukan N; Zorlu E; Karaman Y; Andaç Topkan T; Gurbuz N; Neşelioğlu S; Erel Ö
    J Clin Neurosci; 2020 May; 75():188-194. PubMed ID: 32223973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
    Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
    J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study.
    Marksteiner J; Imarhiagbe D; Defrancesco M; Deisenhammer EA; Kemmler G; Humpel C
    Exp Gerontol; 2014 Feb; 50():114-21. PubMed ID: 24333505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.
    Hunt PJ; Richards AM; Nicholls MG; Yandle TG; Doughty RN; Espiner EA
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):287-96. PubMed ID: 9373449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects.
    Forlenza OV; Miranda AS; Guimar I; Talib LL; Diniz BS; Gattaz WF; Teixeira AL
    J Alzheimers Dis; 2015; 46(2):423-9. PubMed ID: 25737042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of plasma endothelial lipase levels on cognitive impairment.
    Yun SM; Park JY; Seo SW; Song J
    BMC Psychiatry; 2019 Jun; 19(1):187. PubMed ID: 31216999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.